eFFECTOR Therapeutics recently presented Phase 1 clinical trial data for its lead product candidate, eFT508, at the 2017 American Society of Clinical Oncology annual meeting in Chicago.
eFFECTOR’s presentation was titled “A Phase 1 Dose Escalation Study of eFT508, an Inhibitor of Mitogen-Activated Protein Kinase-Interacting Serine/Threonine Kinase-1 (MNK-1) and MNK-2 in Patients with Advanced Solid Tumors.” In the trial, eFT508 was shown to be well tolerated at dosage levels that were sufficient to maximize anti-tumor activity in preclinical models. eFT508, an immuno-oncology therapeutic, works an inhibitor to MNK1/2 kinases that mediate tumor immune invasion.
“The favorable Phase 1 study data will allow eFFECTOR to rapidly expand our clinical development plans for eFT508, including planned Phase 2 studies of eFT508 as monotherapy and in combination with checkpoint inhibitors later this year,” Dr. Steve Worland, president and CEO of eFFECTOR, said in a statement. “We anticipate that we will have initial Phase 2 efficacy data in 2018 which we believe will support eFT508’s potential to improve immunological treatments for cancer."
Alerts Sign-up